A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies

Abstract

Chemotherapy-induced thrombocytopenia (CIT) frequently complicates cancer treatment causing chemotherapy delays, dose reductions, and discontinuation. There is no FDA-approved agent available to manage CIT. This study retrospectively evaluated patients with CIT treated on institutional romiplostim treatment pathways at 4 U.S. centers. The primary outcome was achievement of a romiplostim response [median on-romiplostim platelet count (Plt) ≥75x109/L and ≥30x109/L above baseline]. Secondary outcomes included time to Plt≥100x109/L and rates of the following: Plt<100x109/L, Plt<75x109/L, Plt<50x109/L, thrombocytosis, chemotherapy dose reduction/treatment delay, platelet transfusion, bleeding, and thromboembolism. Multivariable regression was used to identify predictors of romiplostim non-response and compare weekly dosing with intracycle/intermittent dosing. 173 patients (153 solid tumor, 20 lymphoma or myeloma) were treated, with 170 (98%) receiving a median of 4 (range, 1-36) additional chemotherapy cycles on romiplostim. Romiplostim was effective in solid tumor patients: 71% of patients achieved a romiplostim response, 79% avoided chemotherapy dose reductions/treatment delays and 89% avoided platelet transfusions. Median per-patient Plt on romiplostim was significantly higher than baseline (116x109/L vs. 60x109/L, P<0.001). Bone marrow tumor invasion, prior pelvic irradiation, and prior temozolomide predicted romiplostim non-response. Bleeding rates were lower than historical CIT cohorts and thrombosis rates were not elevated. Weekly dosing was superior to intracycle dosing with higher response rates and less chemotherapy dose reductions/treatment delays (IRR 3.00, 95% CI 1.30-6.91, P=0.010) or bleeding (IRR 4.84, 95% CI 1.18-19.89, P=0.029). Blunted response (10% response rate) was seen in non-myeloid hematologic malignancy patients with bone marrow involvement. In conclusion, romiplostim was safe and effective for CIT in most solid tumor patients.

Introduction

Thrombocytopenia is frequent in cancer patients, usually due to myelosuppressive chemotherapy, tumor infiltration of the bone marrow (BM), or infection.¹ Chemotherapy-induced thrombocytopenia (CIT) is a common complication of cytotoxic chemotherapy and many targeted therapies, occurring in approximately 15-25% of patients receiving platinum, taxane, and/or gemcitabine-based regimens.² Currently there is no US Food and Drug Administration (FDA)-approved agent for CIT management. Platelet transfusion offers only temporary, unreliable improvement that is often impractical or impossible to continue for extended periods. Therefore, chemotherapy dose reductions and treatment delays are the current standard of care for the management of CIT, allowing platelet count to recover to the desired count for subsequent administration of cancer-directed treatment. Reduced relative dose intensity (RDI) that results from CIT-related treatment delays and dose reductions may reduce progression- free survival (PFS) and overall survival (OS).^3,4 Conversely, management or prevention of CIT with thrombopoietic agents may maintain RDI and improve OS, particularly in curable malignancies.^5-8 Bleeding in CIT has major consequences for patient outcomes; patients with CIT who develop major bleeding have been shown to have substantially lower OS.⁴

Thrombopoietin receptor agonists (TPO-RA) have been developed and approved for use in immune thrombocytopenia (ITP),⁹ aplastic anemia,¹⁰ hepatitis C-associated thrombocytopenia,¹¹ and perioperative thrombocytopenia.^12-14 Romiplostim is a weekly subcutaneously- administered TPO-RA currently approved to treat ITP. Maximal doses of romiplostim are considerably more potent in raising the platelet count than the oral small molecule TPO-RA in healthy subjects and possibly in ITP,^15-17 making this an ideal agent for investigation into myelosuppressive thrombocytopenias such as CIT. To date, studies of romiplostim to manage CIT have been limited to case series and small single-center studies.^18-21 These studies suggest that romiplostim is effective in raising the platelet count in patients with solid tumors. Predictors of romiplostim non-response, optimal dosing regimens, and use in non-myeloid hematologic malignancies (lymphoma and myeloma) have not been evaluated. Clinical outcomes data more relevant than simple platelet count measurements, such as resumption of treatment without further chemotherapy dose reductions or treatment delays, bleeding, or thrombosis, are limited. The safety of TPO-RA in cancer patients is a concern, as TPORA carry an associated risk for venous thromboembolism (VTE), which could add to the baseline risk associated with malignancy.

The present study aims to address these questions and evaluate romiplostim to manage CIT in a large cohort of both solid tumor and hematologic malignancy patients treated at four affiliated US academic cancer centers. Institutional pathways guided administration of romiplostim at each center. Management of CIT remains an off-label use of romiplostim.

Methods

Patients and data collection

This study was approved by the Institutional Review Board of Partners Healthcare (approval PHS/2015000152). All patients aged ≥18 years with thrombocytopenia treated with romiplostim to support administration of chemotherapy to treat solid tumors or non-myeloid hematologic malignancies (multiple myeloma, Hodgkin lymphoma or aggressive non-Hodgkin lymphoma) between July 1^st 2009 and July 1^st 2019 at the four participating institutions (Massachusetts General Hospital, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, and Newton- Wellesley Hospital) were identified using the Research Patient Data Registry at Partners Healthcare. The specific patient data collected are available in the Online Supplementary Methods.

Institutional romiplostim chemotherapy-induced thrombocytopenia pathways: weekly versus intracycle dosing

Patients qualified to enter their institutional romiplostim CIT pathway after persistent thrombocytopenia (platelet count <100x10⁹/L) at least 3 weeks from the date of last chemotherapy administration or after a delay in chemotherapy regimen initiation ≥1 week due to thrombocytopenia. For solid tumor patients, two institutions utilized a weekly romiplostim CIT pathway in which romiplostim was administered weekly irrespective of timing of chemotherapy administration and two utilized an intracycle romiplostim CIT pathway in which romiplostim was administered primarily on chemotherapy offweeks, on average twice per month (see Figure 1 for dosing pathways). Regardless of pathway, platelet counts were obtained weekly. All hematologic malignancy patients were treated at institutions that employed the weekly romiplostim treatment pathway.

Effectiveness and safety measures

The primary outcome was achievement of a romiplostim response, defined as a median on-romiplostim platelet count ≥75x10⁹/L and at least 30x10⁹/L higher than the pretreatment baseline. Median on-romiplostim platelet counts were used in all analyses comparing individual patient baseline platelet count to individual patient on-romiplostim platelet count. As romiplostim response is a measure of effectiveness over the entire duration of romiplostim treatment, the time from romiplostim initiation to first achievement of platelet count ≥100x10⁹/L was also evaluated. Because there is no universally accepted platelet count threshold that defines CIT recurrence, incidence rates of all measured platelet counts below thresholds of 50x10⁹/L, 75x10⁹/L, and 100x10⁹/L were also evaluated. Similarly, thrombocytosis was defined as >400x10⁹/L and incidence rates were evaluated.

Other clinical outcomes included rates of chemotherapy intensity reduction (dose reduction or treatment delay) specifically for thrombocytopenia and rates of platelet transfusion, bleeding, and arterial or venous thromboembolic events.

Patients treated with romiplostim for CIT but not able to resume chemotherapy were included in analyses of bleeding, VTE, and platelet count outcomes while on romiplostim treatment but not analyses of chemotherapy intensity reduction or platelet transfusion.

Predictors of romiplostim non-response

Predictors of failure to achieve a romiplostim response (referred to hereafter as “predictors of romiplostim nonresponse”) were evaluated using a multivariable logistic model (see Online Supplementary Methods for development of the model).

Statistical analysis

Median individual patient platelet counts on romiplostim support were compared with the pre-romiplostim baseline platelet count with the Wilcoxon signed-rank test. Predictors of romiplostim non-response were identified using a multivariable logistic model (see Online Supplementary Methods).

Solid tumor patients receiving weekly versus intracycle dosing were compared. Rates of thrombosis, bleeding, chemotherapy delay/dose reduction, platelet transfusion, and platelet counts <50x10⁹/L, <75x10⁹/L, <100x10⁹/L, and >400x10⁹/L were compared in the two groups with negative binomial regression models (see Online Supplementary Methods). Baseline and median onromiplostim platelet counts for each group were compared with the Mann-Whitney U test.

Results

Patients' characteristics

A total of 173 patients (153 solid tumor, 20 hematologic malignancy) were treated for CIT with romiplostim to facilitate ongoing chemotherapy administration. Table 1 lists patients' baseline characteristics. Colorectal, hepatobiliary, pancreatic, and gastroesophageal cancers were the most common malignancies in the cohort, accounting for half of all patients treated. A total of 170 patients (98%; 150 solid tumor and 20 hematologic malignancy) were able to receive additional chemotherapy, receiving a median of four (range: 1-36) additional chemotherapy cycles over a median of 10 (range: 2-125) weeks of romiplostim support. This totaled 60.7 patient-years (3,163 patientweeks) of romiplostim treatment of CIT and 1,063 supported cycles of chemotherapy in the entire cohort. Of the hematologic malignancy patients, 13 had aggressive lymphoma and seven had multiple myeloma; all had known BM involvement by tumor.

Platinum, gemcitabine, temozolomide, and taxanebased regimens most commonly precipitated CIT and were most frequently supported with romiplostim. Online Supplementary Table S1 details chemotherapy regimens precipitating CIT and supported on romiplostim.

Romiplostim dosing

For the entire cohort as well as solid tumor patients only, the median starting dose of romiplostim was 3 mg/kg (interquartile range [IQR], 2-3 mg/kg) and the median optimized dose of romiplostim (the dose at which platelet count ≥100x10⁹/L was achieved in patients achieving this threshold) was 3 mg/kg (IQR: 2-5 mg/kg).

The median starting dose for hematologic malignancy patients was 2 mg/kg (IQR: 2-4 mg/kg) and median optimized dose was 3 mg/kg (IQR: 2-5 mg/kg). Only seven (30%) hematologic malignancy patients achieved platelet count ≥100x10⁹/L and were therefore included in this median. Of the 13 hematologic malignancy patients not achieving platelet count ≥100x10⁹/L, only one was titrated to maximum dose romiplostim (10 mg/kg).

Effect of romiplostim on platelet counts and rates of romiplostim response in solid tumor patients

Median individual patient platelet counts on romiplostim were significantly higher than at baseline in the entire cohort (112x10⁹/L vs. 54x10⁹/L; P<0.001) and in solid tumor patients alone (116x10⁹/L vs. 60x109/L; P<0.001). Figure 2A illustrates median weekly platelet counts on romiplostim support for solid tumor patients.

The rate of romiplostim response (achieving a median on-romiplostim platelet count ≥75x10⁹/L and at least 30x10⁹/L higher than the pretreatment baseline) was 71% for all solid tumor patients and 82% for those patients without predictors of romiplostim non-response (see “Predictors of romiplostim non-response in solid tumor patients” below).

Of all 153 solid tumor patients, 130 (85%) achieved platelet count ≥100x10⁹/L on romiplostim therapy, with a median time from romiplostim initiation to achievement of these values of 9 days (interquartile range [IQR] 7-15 days). After excluding patients with predictors of romiplostim non-response (see below), 116 of 122 solid tumor patients (95%) achieved a platelet count ≥100x10⁹/L on romiplostim therapy, with a median time to platelet count ≥100x10⁹/L of 9 days (IQR 7-14 days). Statistics of additional time to platelet count ≥100x10⁹/L are listed in Online Supplementary Table S2.

Table 1.Baseline characteristics of patients (n=173) treated with romiplostim for chemotherapy-induced thrombocytopenia (CIT) and American Joint Committee on Cancer (AJCC) staging.

Predictors of romiplostim non-response in solid tumor patients

Eight different chemotherapeutics administered to patients prior to development of CIT met criteria for inclusion in the multivariable logistic model evaluating predictors of romiplostim non-response: cisplatin, carboplatin, oxaliplatin, gemcitabine, fluorouracil, irinotecan, temozolomide, and the taxane class (paclitaxel, docetaxel, or cabazitaxel). In a multivariable logistic model with romiplostim response as the dependent variable, and age, sex, biopsy-proven tumor BM invasion, prior pelvic irradiation, and these chemotherapeutics as independent variables, three variables predicted a significantly lower likelihood of romiplostim response: BM invasion (odds ratio [OR] 0.029, 95% confidence interval [CI]: 0.0046-0.18; P<0.001), prior pelvic irradiation (OR 0.078, 95%CI: 0.0062-0.98; P=0.048), and prior exposure to temozolomide (OR 0.24, 95%CI: 0.061-0.96; P=0.043). On-romiplostim platelet counts were considerably lower in patients with these characteristics (Figure 2B) and were reflected in rates of romiplostim response of 23%, 20%, and 46%, respectively. Taken together, 14 of 31 of these patients (45%) achieved platelet count ≥100x10⁹/L on romiplostim therapy, with a median time to platelet count ≥100x10⁹/L of 17 days (IQR 8-24 days). This poor rate of response was observed despite substantial romiplostim dose-escalation in these patients (median romiplostim dose, 8 mg/kg [IQR, 5-10 mg/kg]).

Table 2.Venous thromboembolic events in cohort while on romiplostim treatment for chemotherapy-induced thrombocytopenia (CIT) and within 30 days of romiplostim discontinuation.

Table 3.Bleeding events in cohort while on romiplostim treatment for chemotherapy-induced thrombocytopenia (CIT).

Figure 1.Chemotherapy-induced thrombocytopenia (CIT) romiplostim treatment pathways. In the weekly romiplostim dosing pathway, romiplostim is administered weekly irrespective of treatment schedule. In the intracycle romiplostim dosing pathway, romiplostim is dosed on chemotherapy off-weeks, except for chemotherapy regimens employing regular treatment without off-weeks in which case romiplostim is administered every other week. Platelet counts are obtained weekly in both pathways.

Clinical effectiveness and safety outcomes in solid tumor patients

In the 150 solid tumor patients able to continue chemotherapy with romiplostim treatment, number of events and event rates over the 57.7 patient-years at risk were as follows: chemotherapy intensity reduction, 89 events resulting in a rate of 154 events per 100 patientyears at risk; bleeding, 13 events resulting in a rate of 23 events per 100 patient-years at risk; VTE, eight events resulting in a rate of 14 events per 100 patient-years at risk; and platelet transfusion, 62 events resulting in a rate of 107 events per 100 patient-years at risk. Excluding patients with predictors of romiplostim non-response (50.0 patient-years at risk), number and rates of these outcomes declined as follows: chemotherapy intensity reduction, 65 events, rate 130 per 100 patient-years at risk; bleeding, eight events, rate 16 per 100 patient-years at risk; VTE, seven events, rate 14 per 100 patient-years at risk; and platelet transfusion, 13 events, rate 26 events per 100 patient-years at risk. Of all solid tumor patients 118 out of 150 (79%) had no chemotherapy intensity reductions and 133 out of 150 (89%) required no platelet transfusions while on romiplostim. There were no arterial thromboembolic events. Tables 2 and 3, respectively, describe the individual VTE and bleeding events in the patient cohort. No patient died of bleeding or thrombosis. The three patients given romiplostim but not able to resume chemotherapy did not experience bleeding or thrombotic events on romiplostim.

Comparison of weekly romiplostim dosing versus intracycle romiplostim dosing in solid tumor patients

Of the solid tumor patients, 80 were treated on the weekly romiplostim dosing pathway and 73 were treated on the intracycle romiplostim dosing pathway (Figure 1). Table 4 describes differences in clinical and platelet count outcome between the two groups. Patients receiving weekly dosing had a significantly higher median platelet count on romiplostim (143x10⁹/L vs. 106x10⁹/L; P<0.001) and a higher rate of achieving a romiplostim response (81% vs. 63%; P=0.006). Figure 3 illustrates the difference in median weekly platelet counts for each cohort. Using negative binomial regression modeling controlling for demographics and predictors of romiplostim nonresponse, intracycle dosing had higher rates of platelet counts measured <50x10⁹/L, <75x10⁹/L, or <100x10⁹/L (see Table 4 for details), chemotherapy intensity reduction (incidence rate ratio [IRR] 3.00, 95%CI: 1.30-6.91; P=0.010), and bleeding (IRR 4.84, 95%CI: 1.18-19.89; P=0.029) compared with weekly dosing, with similar rates of thromboembolism and platelet transfusion for chemotherapy administration.

Figure 2.Median weekly platelet counts for patients on romiplostim chemotherapy-induced thrombocytopenia (CIT) treatment pathway. (A) Solid tumor patients (n=153). Error bars represent interquartile ranges. (B) Solid tumor patients with no predictors of romiplostim nonresponse (n=122, blue); solid tumor patients with predictors of romiplostim non-response (n=31, gray) including bone marrow (BM) invasion by tumor, prior pelvic irradiation, or prior temozolomide treatment; aggressive lymphoma patients (n=13, red); and myeloma patients (n=7, purple). Error bars omitted for figure clarity. PNR: predictors of romiplostim non-response (includes BM invasion by tumor, prior temozolomide exposure, or prior pelvic irradiation).

Outcomes in hematologic malignancy patients

Median individual patient platelet counts on romiplostim were significantly higher than at baseline: 46x10⁹/L vs. 21x10⁹/L; P=0.003. Figure 2B illustrates median weekly platelet counts on romiplostim support for hematologic malignancy patients. The rate of romiplostim response in hematologic malignancy patients was 10%. Seven of 20 hematologic malignancy patients (35%) achieved a platelet count ≥100x10⁹/L on romiplostim therapy, with a median time to platelet count ≥100x10⁹/L of 24 days (IQR 19-36 days).

In the 20 hematologic malignancy patients treated (for 3.0 patient-years), there were nine chemotherapy intensity reduction events, one bleeding event (which was not fatal), 44 platelet transfusion events, and no thrombotic events.

Additional data on platelet count outcomes and the bleeding event in hematologic malignancy patients are given in Online Supplementary Tables S2 and S3, respectively.

Discussion

Initial studies of platelet growth factors to manage CIT utilized the first-generation thrombopoietic agents rhIL-11 oprelvekin), rhTPO (recombinant human thrombopoietin), and PEG-rhMGDF (pegylated recombinant human megakaryocyte growth and development factor). These agents demonstrated efficacy in CIT management in clinical studies, reducing need for platelet transfusions, increasing overall and nadir platelet counts, and allowing for improved relative dose intensity.^5,22-24 Unfortunately, development of recombinant thrombopoietins was halted in the West due to occurrence of antibodies to PEGrhMGDF with cross-reactivity to native TPO.²⁵ Oprelvekin was FDA-approved for CIT but use was limited due to an unfavorable side-effect profile; this agent is no longer available from the manufacturer. Notably, rhTPO, which is not associated with cross-reactive antibodies, completed development in China where it is a routine component of supportive care in cancer patients.²⁶ More recent emergence of the TPO-RAs romiplostim, eltrombopag, and avatrombopag has renewed interest in pharmacologic CIT management in the West.

Table 4.Solid tumor patient dosing strategy comparison. Rates of platelet count measurements describe the fraction of counts measured beyond a given platelet count threshold (mean rates for all patients in each group are given). Rates of clinical outcomes are exposure-adjusted (given as rates per 100 patient-years at risk).

Four single-center studies, each evaluating between 20-52 solid tumor patients receiving romiplostim for CIT,^18-21 concluded that romiplostim is effective in raising the platelet count in CIT but did not compare different dosing strategies or characterize predictors of romiplostim nonresponse. None of these studies evaluated bleeding, the primary hazard of thrombocytopenia, and only limited data on the impact of romiplostim treatment on chemotherapy dose reductions and treatment delays were described.^20,21 Treatment of CIT with romiplostim in nonmyeloid hematologic malignancy is currently limited to case reports.²⁷ These factors provided the rationale behind the present study which aimed to address each of these important questions.

We found that romiplostim was effective for the management of CIT in solid tumor patients receiving a variety of different chemotherapy regimens, with 98% (150 of 153) able to continue receiving chemotherapy with romiplostim support. Romiplostim treatment more than doubled the median platelet count of the cohort (from 54x10⁹/L to 112x10⁹/L) enabling 79% of solid tumor patients to proceed without further chemotherapy dose reductions or treatment delays due to thrombocytopenia and 89% to proceed without platelet transfusions. The use of romiplostim for CIT in patients with solid tumors may improve outcomes of cancer treatment by allowing maintenance of dose intensity. Weekly romiplostim dosing, as compared with intracycle romiplostim dosing, resulted in fewer recurrences of CIT, chemotherapy dose reductions/treatment delays, and bleeding events (Table 4). Thrombocytosis rates were higher but VTE rates were similar. The lower overall exposure to romiplostim in patients treated with intracycle dosing as compared with weekly dosing may account for the differences in the observed outcomes between these two groups. Of note, intracycle dosing was still an effective strategy and could be considered as this reduces drug-associated costs.

Figure 3.Median weekly platelet counts for solid tumor patients receiving standard weekly romiplostim dosing (n=65, dark blue) versus intracycle romiplostim dosing (n=57, light blue). Patients with predictors of romiplostim non-response (bone marrow invasion, prior pelvic irradiation, or prior temozolomide) were excluded from this figure to emphasize the difference specifically attributable to dosing regimen. Error bars represent interquartile ranges.

Given our large sample size, we were able to evaluate predictors of romiplostim non-response using multivariable logistic modeling; we found that BM invasion by tumor, prior pelvic irradiation, and prior exposure to temozolomide predict poor response to romiplostim treatment. The latter finding is consistent with the distinct risk of temozolomide resulting in severe marrow toxicity,²⁸ made manifest by prolonged cytopenias or even aplastic anemia. Our findings suggest evaluation of CIT patients at high risk for BM involvement by tumor (such as patients with metastatic breast, prostate, or lung cancer with known bony involvement) with a BM biopsy may be appropriate before considering romiplostim treatment. Similarly, patients previously treated with pelvic irradiation or temozolomide may be better served with alternative approaches to CIT management. Studies of other thrombopoietic agents have demonstrated efficacy in treatment of CIT in lymphoma⁵ and demonstrated BM invasion by tumor as a predictor of romiplostim nonresponse in solid tumor patients. Given this, in this study, the overall subpar response of non-myeloid hematologic malignancy patients to romiplostim observed is likely secondary to known BM infiltration by malignancy, although many of these patients were not escalated to maximal doses of romiplostim. Additional studies of romiplostim to treat CIT in lymphoma patients without significant BM involvement are needed to better assess its utility in this population.

With 60.7 patient-years at risk of romiplostim treatment in this study, we were able to meaningfully evaluate rates of thromboembolic and bleeding events on romiplostim treatment. Eight patients developed a VTE event on romiplostim treatment, a rate of 14 VTE events per 100 patientyears. Given that 75% of our patients had metastatic disease (with one-third of those with localized disease having primary central nervous system malignancies which impart a high VTE risk) and approximately half had tumor types associated with higher VTE risk, this rate is consistent with VTE rates of 10-14 events per 100 patient-years described in epidemiologic studies of similar populations. ^29,30 No patient developing VTE had thrombocytosis at the time of VTE diagnosis, with platelet counts ranging between 65-307x10⁹/L (Table 2). Solid tumor patients without predictors of romiplostim non-response had an overall bleeding rate of 16 events per 100 patient-years at risk, consistent with rates in the non-anti-coagulated, nonthrombocytopenic metastatic cancer population.^31,32 This rate is considerably lower than rates in prior studies of CIT patients not treated with thrombopoietic agents. In a large retrospective study of 609 solid tumor and lymphoma patients with 1,262 chemotherapy cycles complicated by CIT, World Health Organization (WHO) grade 3 or 4 bleeding occurred in 43 (3.4%) of cycles.⁴ The rate of WHO grade 3 or 4 bleeding in this study was just 11 out of 1,063 cycles supported with romiplostim (1.0%), and many of these bleeds were likely unrelated to thrombocytopenia (only six occurred at platelet counts <100x10⁹/L and only three occurred at platelet counts <50x10⁹/L) (Table 3). This same retrospective study also found dramatically higher rates of platelet transfusion and chemotherapy dose reduction and treatment delay than those observed in the present study.⁴

Our study has several limitations. As a retrospective, observational study, patients were treated with romiplostim according to institutional pathways that did not mandate strict adherence to treatment parameters. The overall study population was heterogeneous, including a number of different tumor types and chemotherapy regimens. As with many retrospective studies, there is the possibility of selection bias as the patient cohort was defined by those patients enrolled on the romiplostim treatment pathway without evaluating those that were not enrolled. The study was not randomized so cannot quantify the impact of romiplostim treatment compared with a placebo or platelet transfusion-only control group. Although this is the largest study of thrombopoietic growth factor treatment of CIT to date, and the first to include patients with non-myeloid hematologic malignancy, the number of patients with hematologic malignancy was low.

In conclusion, romiplostim is effective for the management of CIT in patients with solid tumors, as demonstrated by improved platelet counts and low rates of chemotherapy dose reductions and treatment delays, bleeding, and platelet transfusions. VTE rates approximated rates in similar cancer populations not receiving romiplostim. Weekly dosing resulted in improved outcomes as compared with more intermittent intracycle dosing. Romiplostim was generally ineffective in patients with BM invasion by tumor, prior pelvic irradiation, and prior exposure to temozolomide.

Footnotes

• Received March 5, 2020
• Accepted May 27, 2020

Correspondence

HANNY AL-SAMKARI hal-samkari@mgh.harvard.edu

Disclosures

HA-S has had a consultancy role for Agios, Dova, Rigel, Argenx, and Sobi, and has received research funding from Agios, Dova, and Amgen; ADP has had a consultancy role for Sunovion, has received research funding from Genentech/Hoffman LaRoche, and Shire/Takeda, and sits on the scientific advisory boards of Bayer, and Shire/Takeda; JIW has had a consultancy role for AbbVie; JMC sits on the scientific advisory boards of Bristol-Myers Squibb, and Portola, has had a consultancy role for Bristol-Myers Squibb, has received personal fees from Bristol-Myers Squibb, and sits on the data safety monitoring board of Unum Therapeutics; DJK has received research funding from Protalex, Bristol-Myers Squibb, Rigel, Bioverativ, Agios, Syntimmune, Principia, and Alnylam, and has had a consultancy role for ONO, Pfizer, 3SBios, Eisai, GlaxoSmithKline, Genzyme, Shire, Amgen, Shionogi, Rigel, Syntimmune, MedImmune, Novartis, Alexion, Bioverativ, Argenx, Zafgen, Fujifilm, Principia, Kyowa Kirin, Takeda, and the Platelet Disorders Support Association.

Contributions

HA-S wrote the first draft of the manuscript and contributed to study design, data collection, data analysis, creation of tables and figures, critical revision of the manuscript, and final approval of the manuscript for publication; ADP contributed to romiplostim treatment pathway design, data collection, revision of the manuscript, and final approval of the manuscript for publication; KG, JIW and JMC contributed to romiplostim treatment pathway design, revision of the manuscript, and final approval of the manuscript for publication; DJK contributed to romiplostim treatment pathway design, critical revision of the manuscript, and final approval of the manuscript for publication.